Rani Therapeutics Holdings, Inc. (RANI) — 10-Q Filings

10-Q Filings (6)

• Rani Therapeutics Narrows Q3 Loss, Boosts Cash Amid Asset Shift — Nov 6, 2025 Risk: high
  Rani Therapeutics Holdings, Inc. reported a net loss of $7.914 million for the three months ended September 30, 2025, a 37.8% improvement from the $12.722 milli
• Rani Therapeutics Narrows Q2 Loss Amidst Continued R&D Spend — Aug 7, 2025 Risk: high
  Rani Therapeutics Holdings, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's n
• Rani Therapeutics Files Q1 2025 10-Q — May 13, 2025 Risk: medium
  Rani Therapeutics Holdings, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported research and development expenses for the
• Rani Therapeutics Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Rani Therapeutics Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its
• Rani Therapeutics Files Q2 2024 10-Q — Aug 6, 2024 Risk: medium
  Rani Therapeutics Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Specific
• Rani Therapeutics Holdings, Inc. Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk: low
  Rani Therapeutics Holdings, Inc. (RANI) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Rani Therapeutics Holdings, Inc. filed a 10-Q report for th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX